BILLERICA, Mass., Aug. 22, 2013 /PRNewswire/ -- Seahorse Bioscience will provide the Cancer Research UK Beatson Institute with its novel XF technology, which measures cell metabolism, to boost research to enable a greater understanding of cancer metabolism and its role in disease progression.
The recently named Director of the Beatson Cancer Metabolism Research Unit, Eyal Gottlieb, Ph.D., will lead the research which will focus on understanding key aspects of cancer cell behavior using the Seahorse XFe96 Extracellular Flux Analyzer.
"My lab combines analytical chemistry, cell biology, and biochemical approaches to study metabolic transformation. These technologies are not only important for understanding the basic biochemistry of cancer cells, but can also inform us on future clinical management of cancer, and may lead to new therapeutic approaches to target cancer-specific metabolic pathways," stated Dr. Gottlieb.
Cancer researchers have a renewed interest in cancer cells' abnormal metabolism of sugar, known as the Warburg effect. Even though oxygen rich conditions favor using the more efficient metabolic pathway via mitochondrial respiration, many cancer cells rely on glycolysis. This is thought to enhance their survival as most solid tumors and their metastases experience periods of low oxygen (hypoxia), where glycolysis is their only source of energy. This reliance on glycolysis promotes both tumor progression and resistance to therapy. These factors and an understanding of the role mitochondria play in regulating cancer growth have stimulated new approaches to deter cancer proliferation. The Seahorse XFe Analyzer is the only analytical instrument that can measure active switching between the two energy pathways critical to cancer cell metabolism: glucose metabolism and mito
|SOURCE Seahorse Bioscience|
Copyright©2012 PR Newswire.
All rights reserved